c*****l
发帖数: 739 | 1 Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into
Technology Development Agreement for ThermoDox� for the Greater China
Territory - MarketWatch
LAWRENCEVILLE, N.J. and TAIZHOU CITY, China, Jan. 22, 2013 /PRNewswire via
COMTEX/ -- Celsion Corporation CLSN -81.17% , a leading oncology drug
development company, and Zhejiang Hisun Pharmaceutical Company Ltd. (sse
code:600267), a leading Chinese pharmaceutical company, today announced that
they have entered into a techno... 阅读全帖 |
|
y*****l
发帖数: 5997 | 2 Celsion Reports First Quarter 2011 Financial Results and Provides Business
Update
Now - Marketwire via Comtex
MarketwireCelsion Corporation (NASDAQ: CLSN), a leading oncology drug
development company, today announced financial results for the first quarter
ended March 31, 2011 and addressed the progress of its clinical trials of
ThermoDox(R), Celsion's proprietary heat-activated liposomal encapsulation
of doxorubicin for the treatment of hepatocellular carcinoma (HCC), commonly
referred to as pr... 阅读全帖 |
|
f**********g
发帖数: 2252 | 3 Celsion Announces Drug Safety Monitoring Board Recommends Advancing DIGNITY
Study of ThermoDox(R) in Recurrent Chest Wall Breast Cancer Into Phase II
1 hours 41 minutes ago - Marketwire via Comtex
MarketwireCelsion Corporation (NASDAQ: CLSN), a leading oncology drug
development company, today announced that after reviewing safety data from
the Company's recently completed Phase I portion of the DIGNITY Phase I/II
study of ThermoDox(R) and hyperthermia in recurrent chest wall (RCW) breast
cancer ... 阅读全帖 |
|
g**********2
发帖数: 2408 | 4 北京时间1月23日上午消息 据美通社报道，肿瘤药物开发公司Celsion Corporation（
克莱瑞恩公司，NASDAQ: CLSN）和中国制药公司浙江海正宣布达成ThermoDox®（
盐酸多柔比星）在大中华区的技术开发协议。
根据协议规定，海正将立即向克莱瑞恩支付500万美元，而克莱瑞恩将向海正提供
它对 ThermoDox® 制造开发计划的支持。以上支付的500万美元不可退还，而且要
在克莱瑞恩于本月晚些时候披露重要三期试验（HEAT 研究）结果之前支付，该试验涉
及肝细胞癌（HCC，又名原发性肝癌）。
此外，两家公司还预计会签署克莱瑞恩给予海正在大中华市场（包括中国大陆、香
港和澳门）独家开发 ThermoDox® 的选择的协议。选择期将受到第二次支付500万
美元的保障，而克莱瑞恩必须在签署上述技术开发协议后60天内获得来自海正的这笔款
项。预期签署的授权协议的关键条款已经经过了商谈，并得到了双方的赞同，为签署最
终合同奠定了基础。
克莱瑞恩总裁兼首席执行官 Michael H. Tardugno 表示：“与海正签署这份协议
让我们可以评估... 阅读全帖 |
|
y*****l
发帖数: 5997 | 5 根据光头的分析，好处是股价便宜，还可能用到其它癌症。但是秋季才有结果，效果如
何未知，有风险，效果好的话上升潜力很大。我不是学生物的，不清楚药效，我估计公
司在下个月的会上有好消息公布。盘子小，生拉风险大，只买一点。
About 93% of the 600 patients in the phase III study of Thermodox are
enrolled, Celsion says. Once 190 tumor progression events occur, independent
data monitors will unblind the study for an interim analysis to determine
whether it can be stopped or if it should continue to the final analysis.
Celsion expects this interim look at the Thermodox study to occur in the
third quarter. If the s... 阅读全帖 |
|
y******1
发帖数: 730 | 6 Thinly-traded nano cap Celsion (NASDAQ:CLSN) jumps 32% premarket on
robust volume in response to its announcement of positive interim results
from a Phase 2 study assessing ThermoDox in combination with mild
hyperthermia in patients with recurrent chest wall breast cancer, a type of
cancer highly resistant to treatment.
Out of the 16 enrolled patients, 12 were eligible for evaluation for
efficacy. Eight (67%) experienced a clinical benefit while seven (58%)
showed a local response, inclu... 阅读全帖 |
|
c*****l
发帖数: 739 | 7 Celsion Corporation : Law Firm Brower Piven Announces Investigation of
Investor Securities Fraud Against Celsion Corporation
01/31/2013| 11:50am US/Eastern
The law firm of Brower Piven, A Professional Corporation, is investigating
potential securities fraud claims against Celsion Corporation ("Celsion") (
NASDAQ: CLSN) regarding whether Celsion may have issued materially false or
misleading information to investors before announcing on January 31, 2013
that its ThermoDox liver cancer treatment f... 阅读全帖 |
|
d**********r
发帖数: 24123 | 8 CLSN fails Phase 3 ThermoDox trial
原来以前Fail掉的是 Phase 3 阿。那要重启的话，10mil 不一定够啊。 |
|
g**a
发帖数: 2129 | 9 The data from the HEAT Study post-hoc analysis presented by Professors
Lencioni and Poon demonstrate that ThermoDox markedly improves PFS and OS in
patients with a single lesion if their lesions undergo RFA for 45 minutes
or more. These findings apply to HCC lesion regardless of size and represent
a subgroup of approximately 300 patients or 42% of the patients in the HEAT
Study.
about 300 single lesion patients? |
|
b*****h
发帖数: 783 | 10 小cap被pump起来，然后融资，
现在risk还是相当大的。他们开发的ThermoDox 大概机理是把广谱抗肿瘤药包在一种热
不稳定脂质体内。等脂质体到了肿瘤里，用微波释放。 效果如何还不能确定，最近会
有三期的interim data。
commitments |
|
f****X
发帖数: 64 | 11 CLSN：
RFA + ThermoDox治疗原发性肝癌，第四季度出HEAT trial的interim结果（估计最早10
月份左右）。Market cap不到100M。
最近insider买了很多。 |
|
